StreetInsider.com News Articles

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (A

Fri, 05 Jun 2026 19:35:00 -0400

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (A

Fri, 05 Jun 2026 19:35:00 -0400

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (A

Fri, 05 Jun 2026 19:35:00 -0400

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (A

Fri, 05 Jun 2026 19:35:00 -0400

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation

MannKind completes randomization in phase 1b study for IPF treatment

Wed, 03 Jun 2026 06:05:17 -0400

MannKind Corporation (NASDAQ: MNKD) announced completion of patient randomization in its Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the Phase 2 INFLO-2 study for nintedanib DPI, a treatment for idiopathic pulmonary fibrosis.

The company expects to report data from the INFLO-1 study in the third quarter of 2026. The study evaluates safety, tolerability, and pharmacokinetics of nintedanib DPI in patients with IPF.

The Phase 2 INFLO-2 study plans to enroll approximately 210 participants across 85 sites worldwide. The first patient was enrolled in Windsor, Canada. This randomized, double-blind, placebo-controlled trial will test nintedanib DPI efficacy and safety

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

Wed, 03 Jun 2026 06:05:00 -0400

Phase 1b INFLO-1 study data readout anticipated in Q3 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the global Phase 2 INFLO-2 study. These milestones mark the advancement of the nintedanib DPI program and

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

Wed, 03 Jun 2026 06:05:00 -0400

Phase 1b INFLO-1 study data readout anticipated in Q3 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the global Phase 2 INFLO-2 study. These milestones mark the advancement of the nintedanib DPI program and

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

Wed, 03 Jun 2026 06:05:00 -0400

Phase 1b INFLO-1 study data readout anticipated in Q3 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the global Phase 2 INFLO-2 study. These milestones mark the advancement of the nintedanib DPI program and

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

Wed, 03 Jun 2026 06:05:00 -0400

Phase 1b INFLO-1 study data readout anticipated in Q3 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the global Phase 2 INFLO-2 study. These milestones mark the advancement of the nintedanib DPI program and

Form 8-K MANNKIND CORP For: May 29

Tue, 02 Jun 2026 08:01:00 -0400
si-local-file:///var/storage/secattach/20260602/26587787.html

Form 8-K MANNKIND CORP For: May 29

Tue, 02 Jun 2026 08:01:00 -0400
si-local-file:///var/storage/secattach/20260602/26587787.html

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Fri, 29 May 2026 14:00:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza^® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at:

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Fri, 29 May 2026 14:00:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza^® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at:

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Fri, 29 May 2026 14:00:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza^® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at:

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Fri, 29 May 2026 14:00:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza^® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at:

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Fri, 29 May 2026 14:00:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at:

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Fri, 29 May 2026 14:00:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at:

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Fri, 29 May 2026 14:00:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at:

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Fri, 29 May 2026 14:00:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at:

US FDA approves MannKind's inhaled insulin for children

Fri, 29 May 2026 12:44:35 -0400

By Sahil Pandey and Sriparna ‌Roy

May 29 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of MannKind's inhaled rapid-acting insulin in children with diabetes, ‌offering patients under 18 years of age a needle-free ⁠treatment option, the company said on Friday.

Shares of the company were up 6% ‌in afternoon trading.

US FDA approves MannKind's inhaled insulin for children

Fri, 29 May 2026 12:44:35 -0400

By Sahil Pandey and Sriparna ‌Roy

May 29 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of MannKind's inhaled rapid-acting insulin in children with diabetes, ‌offering patients under 18 years of age a needle-free ⁠treatment option, the company said on Friday.

Shares of the company were up 6% ‌in afternoon trading.

MannKind gets FDA approval for inhaled insulin in children ages 6 and up

Fri, 29 May 2026 12:30:14 -0400

MannKind Corporation (NASDAQ: MNKD) announced the U.S. Food and Drug Administration approved Afrezza inhaled insulin for children and adolescents aged 6 and older with type 1 and type 2 diabetes.

The approval makes Afrezza the only inhaled mealtime insulin available for pediatric patients in the United States. The treatment delivers insulin through the lungs using MannKind's Technosphere drug-delivery platform and is taken at the start of meals.

More than 350,000 children and adolescents in the United States live with diabetes, with the majority having type 1 diabetes requiring lifelong insulin therapy, according to the company's press release.

The FDA approval was supported by

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

Fri, 29 May 2026 12:30:00 -0400

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day
Approval advances pediatric diabetes care by introducing a new inhaled mealtime insulin option recognized in the American Diabetes Association (ADA) Standards of Care alongside multiple daily injections (MDI) and insulin pumps
Approval is supported by results from the Phase 3 INHALE-1 study in pediatric patients, along with clinical efficacy and safety evidence generated across thousands of patients over the past 20+ years of Technosphere^® inhaled insulin development
Eligible patients can access Afrezza today for $35 or less

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

Fri, 29 May 2026 12:30:00 -0400

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day
Approval advances pediatric diabetes care by introducing a new inhaled mealtime insulin option recognized in the American Diabetes Association (ADA) Standards of Care alongside multiple daily injections (MDI) and insulin pumps
Approval is supported by results from the Phase 3 INHALE-1 study in pediatric patients, along with clinical efficacy and safety evidence generated across thousands of patients over the past 20+ years of Technosphere^® inhaled insulin development
Eligible patients can access Afrezza today for $35 or less

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

Fri, 29 May 2026 12:30:00 -0400

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day
Approval advances pediatric diabetes care by introducing a new inhaled mealtime insulin option recognized in the American Diabetes Association (ADA) Standards of Care alongside multiple daily injections (MDI) and insulin pumps
Approval is supported by results from the Phase 3 INHALE-1 study in pediatric patients, along with clinical efficacy and safety evidence generated across thousands of patients over the past 20+ years of Technosphere^® inhaled insulin development
Eligible patients can access Afrezza today for $35 or less